Programme

Sunday January 28, 2024

13:00 Registration

14:45 Opening Remarks

Dr Klemens HOEGENAUER (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) Dr Karl Heinz KRAWINKLER (NOVARTIS PHARMA AG DEVELOPMENT, Basel, Switzerland) Dr Antonia F. STEPAN (F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

14:59 Recent Developments in Synthetic Methodologies and their Impact

Session Chair

Dr Fabrice GALLOU (NOVARTIS PHARMA, Basel, Switzerland)

15:00 Organic Reactions in Aqueous Medium enabled by Surfactants (PL01)

Dr Niginia BORLINGHAUS (UNIVERSITY OF KONSTANZ, Konstanz, Germany)

15:30 Reagents and Catalysts with Translational Potential (PL02)

Dr Josep CORNELLA COSTA (MAX PLANCK INSTITUTE FOR COAL RESEARCH, Mülheim an der Ruhr, Germany)

16:00 Coffee Break

16:30 From Batch to Flow: Advancing Synthetic Organic Chemistry through Technological Innovation (PL03)

Prof. Timothy NOËL

(UNIVERSITY OF AMSTERDAM, Amsterdam, The Netherlands)

17:00 Chemo-Biocatalytic Processes Enabled by a Continuous Flow Set Up (PL04)

Prof. Francesca PARADISI (UNIVERSITY OF BERN, Bern, Switzerland)

17:30 Break

17:45 New Catalytic Approaches for Simplifying Complex Molecule Synthesis (KL01)

Prof. Darren J. DIXON (UNIVERSITY OF OXFORD, Oxford, United Kingdom)

18:45 Welcome Reception, Sponsored by abcr

20:15 End of the day

Programme

Monday January 29, 2024

From Underground to Mainstream: Neglected and Novel, Emerging Functional Groups for Drug Discovery

Session Chair

Dr Ulrich LÜCKING (FORX THERAPEUTICS, Basel, Switzerland)

08:30 Boron Based Heterocycles and their Application in Drug Discovery (PL05)

Prof. Bhaskar DAS

(LONG ISLAND UNIVERSITY, Brooklyn, United States)

09:00 "Magic Chloro": Profound Effects of the Chlorine Atom in Drug Discovery (PL06)

Dr Yoshihiro ISHIHARA (VIVIDION THERAPEUTICS, San Diego, United States)

09:30 Coffee Break

10:00 Deuterium in Drug Design: From Deuterium Switch to De Novo Drug Discovery (PL07)

Prof. Tracey PIRALI (UNIVERSITY OF PIEMONTE ORIENTALE, Novara, Italy)

10:30 New Functional Groups for Synthetic and Discovery Chemistry (PL08)

Prof. Michael WILLIS (UNIVERSITY OF OXFORD, Oxford, United Kingdom)

11:00 Outdoor Networking Activities

16:00 Networking Break

16:15 In Silico Prediction of Phase I and II Metabolism: Guiding Optimisation of Drug Metabolism o_BR Company Workshop by Optibriumc_BR

Dr Matthew SEGALL (OPTIBRIUM LTD, Cambridge, United Kingdom)

Latest Advances and Approaches in Bioconjugation Drug Discovery

Session Chair

Dr Karl Heinz KRAWINKLER (NOVARTIS PHARMA AG DEVELOPMENT, Basel, Switzerland)

17:00 Bicyclic Peptides as a Novel Therapeutic Modality (PL09)

Dr Philip MURRAY (BICYCLE THERAPEUTICS, Cambridge, United Kingdom) (SOPLVIAS AG (WAS FUJIFILM))

17:30 Next-Generation Bioconjugates for Intra- and Extracellular Targeting (PL10)

Prof. Christian HACKENBERGER (FMP BERLIN, Berlin, Germany)

18:00 Coffee Break

Programme

18:30	Creating Next-Generation Biotherapeutics Using Novel Chemistry Platform Technologies (PL11) Dr Vijaya R. PATTABIRAMAN (BRIGHT PEAK THERAPEUTICS, Basel, Switzerland)
19:00	Exploring the Versatility of Covalent and Supramolecular Bioconjugation in ADC and AOC (PL12) Dr Alain WAGNER (CNRS/UNIVERSITY OF STRASBOURG, Illkirch, France)
19:30	Poster Session 1 (odd numbers)
20:30	End of the Poster Session

Programme

Tuesday January 30, 2024

Human Dose Prediction in the Discovery Space

Session Chair

Dr Holger FISCHER (F. HOFFMANN-LA ROCHE LTD., BASEL, Switzerland)

08:30 Early Human Dose Predictions in Lead Optimization (PL13)

Dr Johan BYLUND

(CTC CLINICAL TRIAL CONSULTANTS AB, Uppsala, Sweden)

09:00 Early Human Dose Prediction & Machine Learning Models - Can We Impact Lead Selection? (PL14)

Dr Gregori GEREBTZOFF

(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

09:30 Coffee Break

10:00 SwiftPK: Development and Implementation of a High Throughput PBPK/PD Framework to Inform Drug Selection in Early Drug Discovery (PL15)

Dr Andres OLIVARES (F. HOFFMANN-LA ROCHE, Basel, Switzerland)

10:30 Predicting Human Exposure and Dose of Compounds Targeting the Brain (PL16)

Dr Nicola COLCLOUGH (ASTRAZENECA, Cambridge, United Kingdom)

11:00 Outdoor Networking Activities

15:30 Networking Break

Antiviral Drug Discovery

Session Chair

Dr Dafydd OWEN (PFIZER, Cambridge, United States)

16:30 Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Option for Acyclovir-Resistant Herpes Simplex Virus Infections (PL17)

Dr Alexander BIRKMANN (AICURIS ANTI-INFECTIVE CURES AG, Wuppertal, Germany)

17:00 Targeting Viral RNA Degradation Via Small Molecules As a Novel Antiviral Strategy to Achieve HBV Cure (PL18)

Dr Dimitar GOTCHEV (ARBUTUS BIOPHARMA, Doylestown, United States)

17:30 Coffee Break

18:00 Direct-Acting Antivirals with a Targeted Protein Degradation Mechanism (PL19)

Programme

Prof. Priscilla YANG (STANFORD UNIVERSITY, Stanford, United States)

18:30 Discovery of Obeldesivir; Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys (PL20)

Dr. Doo KALLA

(GILEAD SCIENCES, Foster City, United States)

19:00 The Discovery of PAXLOVID (KL02)

Dr Dafydd OWEN (PFIZER, Cambridge, United States)

20:00 End of the Scientific Programme

20:30 Conference Dinner

Programme

Wednesday January 31, 2024

08:29 Radical Intermediates in Complex Molecule Synthesis

Session Chair

Prof. Nina HARTRAMPF (UNIVERSITY OF ZURICH, Zürich, Switzerland)

08:30 Light-Mediated Nickel Catalysis Enabled by Donor-Acceptor Ligands (PL21)

Prof. Bart PIEBER (INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA (ISTA), Klosterneuburg, Austria) (SOPLVIAS AG (WAS FUJIFILM))

09:00 Recent Adventures in Catalysis and Beyond (PL22)

Prof. Bill MORANDI (ETH ZÜRICH, Zürich, Switzerland)

09:30 Coffee Break

10:00 Alkenes as Flexible Platforms for Asymmetric Transformations (PL23)

Prof. Cristina NEVADO (UNIVERSITY OF ZURICH, Zurich, Switzerland)

10:30 Attempts to Deliver on the Promise of Natural Product Synthesis (PL24)

Prof. Ryan SHENVI (SCRIPPS RESEARCH, La Jolla, United States)

11:00 Outdoor Networking Activities

16:00 Networking Break

16:15 Al for Medicinal Chemists: Novel Compounds Design and Retrosynthesis Prediction o_BR*Company Workshop by Iktosc_*BR

Dr Quentin PERRON (IKTOS, Paris, France)

16:59 Drug Discovery Tales I

Session Chair

Dr Scott WOLKENBERG (JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON, Spring House, United States)

17:00 NLRP3 Inhibitors for Neurodegenerative Disorders (OC01)

Dr Oscar MAMMOLITI (JANSSEN RESEARCH & DEVELOPMENT, Beerse, Belgium)

17:30 Discovery of a Bivalent Protein Kinase CK2 Inhibitor with Activity in Renal Cell Carcinoma (OC02)

Dr Isabelle KRIMM (CLB, Lyon, France)

17:50 Coffee Break

Programme

18:20 Discovery of BI 7446: A Potent Cyclic Dinucleotide Sting Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer (OC03)

Dr Christian KUTTRUFF

(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach, Germany)

18:40 Discovery of [18F]RoSMA-18-D6 for PET Imaging of Cannabinoid Type 2 Receptors (OC04)

Dr Luca GOBBI

(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

19:00 Selective Inhibition of Tead Transcription and Impact on the Up-Stream Effector Kinases of the Hippo

Pathway to Halt Metastatic Colorectal Cancer Cell Growth (OC05)

Prof. Maria Paola COSTI

(UNIVERSITY OF MODENA AND REGGIO EMILIA, Modena, Italy)

19:20 Poster Session 2 (even numbers)

20:30 End of the Poster Session

Programme

	Thursday	February	1, 2024
--	----------	-----------------	---------

08:29	Crvo-FM-	Annlications	for	Structure-Based	Drug	Discovery
UU.Z3	OI YO-LIVI.	ADDIIGATIONS	101	Oli uctui e-Daseu	річч	DISCOVEIV

Session Chair

Dr Katharina DÜRR

(OMASS THERAPEUTICS, Oxford, United Kingdom)

08:30 Deep Learning-Driven De Novo Drug Design Based on Gastric Proton Pump Structure (PL25)

Prof. Kazuhiro ABE

(NAGOYA UNIVERSITY, Nagoya, Japan)

09:00 Cryo-EM Enables Structure-Based Drug Design for Membrane Protein Targets at BI (PL26)

Dr Rebecca EBENHOCH

(BOEHRINGER INGELHEIM, Biberach, Germany)

09:30 Coffee Break

10:00 Single Particle CryoEM at 200 kV & Itchy GPRCs (PL27)

Prof. Jonathan F. FAY

(UNIVERSITY OF NORTH CAROLINA CHAPEL HILL, Chapel Hill, United States)

10:30 Examples from Structure-Based Drug Discovery Using Cryo-EM at MSD (PL28)

Dr Harini KRISHNAMURTHY

(MERCK, SHARP & DOHME, Blue Bell, United States)

11:00 Outdoor Networking Activities

16:00 Networking Break

16:59 Drug Discovery Tales II

Session Chair

Dr Scott WOLKENBERG

(JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON, Spring House, United States)

17:00 Discovery of a Novel Oral NO- and Heme-Independent sGC Activator Runcaciguat (BAY 1101042) (OC06)

Dr Michael G. HAHN

(BAYER AG PHARMACEUTICALS, Wuppertal, Germany)

17:30 Heterocyclic Compounds as Delta-5 Desaturase Inhibitors (OC07)

Dr Ana MINATTI

(AMGEN INC, Copenhagen, Denmark)

18:00 Coffee Break

18:30 Novel Approaches to Molecular Glue Discovery: Design of Clinical Candidate NVP-DKY709 an IKZF2 Degrader by Re-Programming of CRBN Selectivity and Screening for Cooperativity Using DNA Encoded Libraries (OC8)

Programme

Dr Frédéric ZECRI (NOVARTIS, Cambridge, United States)

19:00 Discovery of LY3154885, a Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Drug-Drug Interaction Risk Profile (OC09)

Dr Erik HEMBRE (ELI LILLY AND COMPANY, Indianapolis, United States)

19:30 Site-Selective C—H Oxidations for Late-Stage Functionalizations (KL03)

Prof. M. Christina WHITE (UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN, Urbana, United States)

20:30 Closing Remarks